Elevated Soluble Podoplanin Associates with Hypercoagulability in Patients with Nephrotic Syndrome

被引:5
作者
Ji, Ying [1 ]
Wang, Yan-Li [2 ]
Xu, Fang [1 ]
Jia, Xi-Bei [1 ]
Mu, Su-Hong [1 ]
Lyu, Hui-Yan [1 ]
Yuan, Xue-Ying [1 ]
Na, Shi-Ping [1 ]
Bao, Yu-Shi [1 ]
机构
[1] Harbin Med Univ, Affiliated Hosp 1, Dept Nephrol, 23 Youzheng St, Harbin 150001, Peoples R China
[2] Harbin Med Univ, Affiliated Hosp 1, Dept Rheumatol, Harbin, Peoples R China
关键词
podoplanin; C-type lectin-like receptor 2; nephrotic syndrome; hypercoagulable state; thrombosis; VENOUS THROMBOSIS; TUMOR-METASTASIS; RECEPTOR CLEC-2; THROMBOEMBOLISM; PLATELETS; INTEGRITY; ROLES; MICE;
D O I
10.1177/10760296221108967
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Podoplanin (PDPN) promotes platelet aggregation and activation by interacting with C-type lectin-like receptor 2(CLEC-2) on platelets. The interaction between the upregulated PDPN and platelet CLEC-2 stimulates venous thrombosis. PDPN was identified as a risk factor for coagulation and thrombosis in inflammatory processes. Hypercoagulability is defined as the tendency to develop thrombosis according to fibrinogen and/or D dimer levels. Nephrotic syndrome is also considered to be a hypercoagulable state. The aim of this study is to investigate the association of soluble PDPN/CLEC-2 with hypercoagulability in nephrotic syndrome. Thirty-five patients with nephrotic syndrome and twenty-seven healthy volunteers were enrolled. PDPN, CLEC-2 and GPVI concentrations were tested by enzyme-linked immunosorbent assay (ELISA). Patients with nephrotic syndrome showed higher serum levels of PDPN and GPVI in comparison to healthy controls (P < .001, P = .001). PDPN levels in patients with nephrotic syndrome were significantly correlated with GPVI (r = 0.311; P = .025), hypoalbuminemia (r = -0.735; P < .001), hypercholesterolemia (r = 0.665; P < .001), hypertriglyceridemia (r = 0.618; P < .001), fibrinogen (r = 0.606; P < .001) and D-dimer (r = 0.524; P < .001). Area under the curve (AUC) for the prediction of hypercoagulability in nephrotic syndrome using PDPN was 0.886 (95% CI 0.804-0.967, P < .001). Cut-off value for the risk probability was 5.88 ng/ml. The sensitivity of PDPN in predicting hypercoagulability was 0.806, and the specificity was 0.846. When serum PDPN was >5.88 ng/ml, the risk of hypercoagulability was significantly increased in nephrotic syndrome (OR = 22.79, 95% CI 5.92-87.69, P < .001). In conclusion, soluble PDPN levels were correlated with hypercoagulability in nephrotic syndrome. PDPN has the better predictive value of hypercoagulability in nephrotic syndrome as well as was a reliable indicator of hypercoagulable state.
引用
收藏
页数:7
相关论文
共 50 条
  • [1] Elevated Soluble Podoplanin Associates with Hypercoagulability in Patients with Nephrotic Syndrome
    Ji, Ying
    Wang, Yan-Li
    Xu, Fang
    Jia, Xi-Bei
    Mu, Su-Hong
    Lyu, Hui-Yan
    Yuan, Xue-Ying
    Na, Shi-Ping
    Bao, Yu-Shi
    CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, 2022, 28
  • [2] Elevated Soluble Podoplanin Associates with Hypercoagulability in Patients with Nephrotic Syndrome
    Ji, Ying
    Wang, Yan-Li
    Xu, Fang
    Jia, Xi-Bei
    Mu, Su-Hong
    Lyu, Hui-Yan
    Yuan, Xue-Ying
    Na, Shi-Ping
    Bao, Yu-Shi
    CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, 2022, 28
  • [3] Association of elevated circulating monocyte-platelet aggregates with hypercoagulability in patients with nephrotic syndrome
    Na, Shi-Ping
    Ning, Mei-Liang
    Ma, Ji-Fang
    Liang, Shuang
    Wang, Yan-Li
    Sui, Man-Shu
    Guo, Xiao-Fang
    Ji, Ying
    Lyu, Hui-Yan
    Yuan, Xue-Ying
    Bao, Yu-Shi
    THROMBOSIS JOURNAL, 2024, 22 (01):
  • [4] Hypercoagulability and Nephrotic Syndrome
    Gigante, Antonietta
    Barbano, Biagio
    Sardo, Liborio
    Martina, Paola
    Gasperini, Maria L.
    Labbadia, Raffaella
    Liberatori, Marta
    Amoroso, Antonio
    Cianci, Rosario
    CURRENT VASCULAR PHARMACOLOGY, 2014, 12 (03) : 512 - 517
  • [5] ELEVATED PLASMA LIPOPROTEIN(A) IN PATIENTS WITH THE NEPHROTIC SYNDROME
    WANNER, C
    RADER, D
    BARTENS, W
    KRAMER, J
    BREWER, HB
    SCHOLLMEYER, P
    WIELAND, H
    ANNALS OF INTERNAL MEDICINE, 1993, 119 (04) : 263 - 269
  • [6] Plasma Soluble Podoplanin as a Biomarker of Hypercoagulability and Cellular Immunity Status in Patients With Non-small Cell Lung Cancer
    Zhang, Qian
    Peng, Kun
    Wang, Lin
    Zhang, Ru-Yu
    Xin, Li-Hong
    Huang, Jing-Ying
    Zhang, Yan-Min
    Zhao, Jie
    CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, 2023, 29
  • [7] ELEVATED LIPOPROTEIN-(A) LEVELS IN PRIMARY NEPHROTIC SYNDROME
    FAUCHER, C
    DOUCET, C
    BAUMELOU, A
    CHAPMAN, J
    JACOBS, C
    THILLET, J
    AMERICAN JOURNAL OF KIDNEY DISEASES, 1993, 22 (06) : 808 - 813
  • [8] Hypercoagulability risk factors associated with venous thromboembolic events in patients with idiopathic membranous nephropathy and nephrotic syndrome: a prospective observational study
    Ismail, Gener
    Harza, Mihai
    Tuta, Liliana
    Jurubita, Roxana
    Motoi, Otilia
    Ditoiu, Alecse Valerian
    REVISTA ROMANA DE MEDICINA DE LABORATOR, 2013, 21 (2-4): : 135 - 143
  • [9] Mechanisms of hypercoagulability in nephrotic syndrome associated with membranous nephropathy as assessed by thromboelastography
    Huang, Meng-jie
    Wei, Ri-bao
    Wang, Zi-cheng
    Xing, Yue
    Gao, Yu-wei
    Li, Min-xia
    Cai, Guang-yan
    Chen, Xiang-mei
    THROMBOSIS RESEARCH, 2015, 136 (03) : 663 - 668
  • [10] The Detection of Plasma Soluble Podoplanin of Patients with Breast Cancer and Its Clinical Signification
    Zhu, Xinyi
    Xu, Mengqiao
    Zhao, Xingpeng
    Shen, Fei
    Ruan, Changgeng
    Zhao, Yiming
    CANCER MANAGEMENT AND RESEARCH, 2020, 12 : 13207 - 13214